PRESERVE TRIAL: Pancreatic beta-cell dysfunction restored by rosiglitazone and valsartan effects. A 52-week randomized controlled factorial study in subjects with IFG and/or IGT.

Trial Profile

PRESERVE TRIAL: Pancreatic beta-cell dysfunction restored by rosiglitazone and valsartan effects. A 52-week randomized controlled factorial study in subjects with IFG and/or IGT.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2013

At a glance

  • Drugs Valsartan (Primary)
  • Indications Glucose intolerance; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PRESERVE
  • Most Recent Events

    • 06 Jan 2010 Status changed from planning to completed as reported by Netherlands Trials Register record.
    • 26 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top